Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Datroway (datopotamab deruxtecan)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca, Daiichi Sankyo

Drug class:

Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate

Related drugs:

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

PF-08046044 (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	datopotamab deruxtecan Sensitive: B - Late Trials datopotamab deruxtecan Sensitive : B	datopotamab deruxtecan Sensitive: B - Late Trials datopotamab deruxtecan Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	datopotamab deruxtecan Sensitive: B - Late Trials datopotamab deruxtecan Sensitive : B	datopotamab deruxtecan Sensitive: B - Late Trials datopotamab deruxtecan Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	datopotamab deruxtecan Sensitive: C2 – Inclusion Criteria datopotamab deruxtecan Sensitive : C2	datopotamab deruxtecan Sensitive: C2 – Inclusion Criteria datopotamab deruxtecan Sensitive : C2
TROP2 overexpression	Non Small Cell Lung Cancer	TROP2 overexpression	Non Small Cell Lung Cancer	datopotamab deruxtecan Sensitive: C3 – Early Trials datopotamab deruxtecan Sensitive : C3	datopotamab deruxtecan Sensitive: C3 – Early Trials datopotamab deruxtecan Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab + datopotamab deruxtecan Sensitive: C3 – Early Trials pembrolizumab + datopotamab deruxtecan Sensitive : C3	pembrolizumab + datopotamab deruxtecan Sensitive: C3 – Early Trials pembrolizumab + datopotamab deruxtecan Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + datopotamab deruxtecan Sensitive: C3 – Early Trials pembrolizumab + datopotamab deruxtecan Sensitive : C3	pembrolizumab + datopotamab deruxtecan Sensitive: C3 – Early Trials pembrolizumab + datopotamab deruxtecan Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	pembrolizumab + datopotamab deruxtecan Sensitive: C3 – Early Trials pembrolizumab + datopotamab deruxtecan Sensitive : C3	pembrolizumab + datopotamab deruxtecan Sensitive: C3 – Early Trials pembrolizumab + datopotamab deruxtecan Sensitive : C3
TROP2 expression	Breast Cancer	TROP2 expression	Breast Cancer	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D
TROP2 expression	Non Small Cell Lung Cancer	TROP2 expression	Non Small Cell Lung Cancer	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D
TROP2 expression	Colon Cancer	TROP2 expression	Colon Cancer	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D
TROP2 overexpression	Breast Cancer	TROP2 overexpression	Breast Cancer	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D	datopotamab deruxtecan Sensitive: D – Preclinical datopotamab deruxtecan Sensitive : D